跳至主要内容
临床试验/NCT01896583
NCT01896583已完成2 期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Seldar Pharma, Inc.13 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
64
试验地点
13
主要终点
Abdominal pain

研究概览

简要总结

This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to provide written informed consent
  • Men or women aged 18-75 years
  • Patient has IBS with diarrhea (IBS-D)
  • Ability to communicate with the investigator

排除标准

  • IBS with constipation (IBS-C) or mixed IBS (IBS-M)
  • Other significant disease or condition that may interfere with trial completion
  • Untreated lactose intolerance
  • History of alcohol or drug abuse in past two years
  • Participation in other clinical trials within prior month

研究组 & 干预措施

ASP7147

Experimental

ASP7147, 300 mg, tablet, twice per day for 4 weeks oral

干预措施: ASP7147 (Drug)

Placebo

Placebo Comparator

oral

干预措施: Placebo (Drug)

结局指标

主要结局

Abdominal pain

时间窗: 4 weeks

10-point pain scale

次要结局

  • Stool consistency(4 weeks)
  • Stool frequency(4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验